Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -78.88% | 661.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -78.88% | 661.44% | |||
| Cost of Revenue | -- | 66.44% | |||
| Gross Profit | -76.37% | 1,226.11% | |||
| SG&A Expenses | -12.32% | -7.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -46.12% | 1.07% | |||
| Operating Income | 31.45% | 27.19% | |||
| Income Before Tax | 40.13% | -2.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.34% | -12.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.34% | -12.55% | |||
| EBIT | 31.45% | 27.19% | |||
| EBITDA | 31.95% | 27.58% | |||
| EPS Basic | 45.98% | -10.98% | |||
| Normalized Basic EPS | 40.85% | -1.34% | |||
| EPS Diluted | 45.98% | -10.98% | |||
| Normalized Diluted EPS | 40.85% | -1.34% | |||
| Average Basic Shares Outstanding | 1.20% | 1.41% | |||
| Average Diluted Shares Outstanding | 1.20% | 1.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||